Nabriva Therapeutics Prices Initial Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/12/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Wall Street ends higher as investors turn to earnings season
Nabriva Therapeutics AG (NBRV) IPO Opens Up 8%
September 18, 2015 11:24 AM EDTToday's IPO for Nabriva Therapeutics AG (NASDAQ: NBRV) opened for trading at $11.39 after pricing 9,000,000 American Depositary Shares (ADSs), representing 900,000 of its common shares, at a public offering price of $10.25 per ADS. The pricing was a smidge below the expected... More
Nabriva Therapeutics AG (NBRV) IPO Prices at $10.25/ADS, Slightly Below Expectations
September 18, 2015 8:46 AM EDTNabriva Therapeutics AG (NASDAQ: NBRV) announced he pricing of its initial public offering of 9,000,000 American Depositary Shares (ADSs), representing 900,000 of its common shares, at a public offering price of $10.25 per ADS. The pricing was a smidge below the expected $10.50/ADS. Shares are... More
